Cookie Policy

Mereo BioPharma Group plc's website uses cookies. By continuing to browse you are agreeing to our use of cookies. Find out more about our Cookie Policy.

MREO: US$1.43
Mereo-Banner-Image.jpg

Working together to inspire, innovate and improve lives

See our latest news

News

22 Dec 2021 Mereo & UAB Announce Positive Top-line Results from the Phase 1b/2 COSTA study
13 Dec 2021 Biomarker Data from Phase 1b/2 Trial of Alvelestat in Bronchiolitis Obliterans Syndrome (BOS)
30 Nov 2021 Mereo Reports Interim Data from ACTIVATE Phase 1b/2 Study of Etigilimab
Press Releases

View our latest Corporate Presentation

section-img.jpg
4 JAN 2022 Corporate Presentation
30 NOV 2021 Mereo Reports Interim Data from ACTIVATE Phase 1b/2 Study of Etigilimab VIEW WEBCAST
profile-img.jpg
quote.svg

We continue to make strong progress in development of our product portfolio, in the hope of providing better treatment options for patients with life limiting oncology and rare diseases

Denise Scots-Knight, CEO Our Mission